Author information from the last article
E-post: karln@ous-hf.no
Spesialsykehuset for epilepsi
Oslo universitetssykehus
Karl O. Nakken er dr.med., spesialist i nevrologi og pensjonert overlege.
Articles by Karl O. Nakken
Post-stroke epilepsy
- Karl O. Nakken,
- Morten I. Lossius,
- Erik Sætre,
- Gernot Hlauschek,
- Anette Huuse Farmen
08.08.2024:
Epilepsy as a result of stroke is currently the most rapidly increasing form of epilepsy. The risk of post-stroke epileptogenesis is higher after haemorrhagic stroke than after ischemic stroke. We provide here a brief clinical review of the topic to highlight the misinterpretation and undertreatment...
The fair-haired giant
- Karl O. Nakken,
- Torleiv Svendsen,
- Erlend Hem
27.06.2022:
The much-loved fictional character of Jonas Fjeld is a heroic surgeon. But who was he modelled on? It may have been Dr. Tandberg at Lillehammer. In the period between 1911 and 1935, Øvre Richter Frich (1872–1945) wrote twenty-one books about a fictional surgeon and general super-hero, Jonas Fjeld,...
From hysteroepilepsy to non-epileptic seizure
- Karl O. Nakken,
- Antonia Villagran
08.03.2021:
Seizures that resemble epileptic seizures but are not related to epilepsy, should be called non-epileptic seizures, even though the expression is not completely precise. There are many kinds of seizures that greatly resemble epileptic seizures but that are not related to epilepsy. The most common...
Are the new anti-epileptic drugs any better than their predecessors?
- Karl O. Nakken,
- Eylert Brodtkorb
23.11.2020:
Since 1993, fifteen new anti-epileptic drugs have entered the market. But while the potential for personalised treatment has never been greater, the proportion of patients achieving seizure freedom is no higher than it was before. Prior to 1993, the treatment of epilepsy was largely dominated by...
Discontinuation of antiepileptic drugs in seizure-free patients – when and how?
- Morten I. Lossius,
- Kristin Å. Alfstad,
- Kari M. Aaberg,
- Karl O. Nakken
21.03.2017:
In seizure-free patients with epilepsy, the question of whether, and if so when, it is acceptable to discontinue treatment may be difficult to answer. A thorough risk-benefit assessment should be undertaken with the patient and next of kin, during which the consequences of a relapse must be weighed...